Letrozole is a medication used to treat certain types of breast cancer in women who have gone through menopause. It works by blocking an enzyme that helps the body make estrogen. It's often used after other treatments have stopped working. It's a type of drug called an aromatase inhibitor.
Every report comes from a Lived member, sent anonymously.
Have you tried Femara (Letrozole) for Breast Cancer?
Letrozole, sold under the brand name Femara and as a generic, is a prescription pill used to treat hormone receptor positive breast cancer in women who have gone through menopause. Hormone receptor positive means the cancer cells carry receptors for estrogen or progesterone, so estrogen can fuel their growth. Letrozole is approved after surgery for early breast cancer to lower the chance of the cancer coming back, as an extended treatment for women who have already completed five years of tamoxifen, and as treatment for breast cancer that is advanced or has spread. Letrozole belongs to a group of medicines called aromatase inhibitors. For advanced breast cancer, and for some early breast cancers at high risk of returning, an aromatase inhibitor such as letrozole may be paired with ribociclib (Kisqali), a targeted cancer pill approved for use alongside it. Before menopause the ovaries make most of the body's estrogen, so for higher-risk premenopausal women an aromatase inhibitor is used only together with treatment that switches off the ovaries, called ovarian suppression. Letrozole also has a second, very different use. Fertility specialists prescribe it off-label (for a use not listed on its U.S. Food and Drug Administration label) to help people with polycystic ovary syndrome (PCOS) who do not ovulate regularly release an egg. International guidelines now recommend it as the first-choice pill for this purpose, ahead of clomiphene. In fertility care it is taken for only a few days per cycle, not daily for years.
After menopause, the ovaries no longer make much estrogen. Most of the estrogen that remains is produced by an enzyme called aromatase, which converts hormones from the adrenal glands into estrogen in tissues such as fat, and in some breast tumors themselves. Letrozole blocks aromatase, which sharply lowers estrogen levels throughout the body. Breast cancers that depend on estrogen lose a growth signal, which can slow or stop their growth and reduce the chance that the cancer returns after surgery. This differs from tamoxifen, another common hormone treatment for breast cancer. Tamoxifen blocks estrogen from acting on cancer cells, while letrozole reduces how much estrogen is made in the first place. That difference helps explain why the two drugs have different side effects: the very low estrogen level on letrozole tends to affect bones and joints, while tamoxifen carries more risk of blood clots and uterine cancer. In fertility treatment, letrozole is given briefly at the start of a menstrual cycle. The short drop in estrogen helps the ovaries mature and release an egg, without the longer-lasting effects of daily use.
For breast cancer, letrozole is a 2.5 mg tablet taken once a day, with or without food. Taking it at about the same time each day makes it easier to remember. After surgery for early breast cancer, it is usually taken for about five years, and some people continue hormone treatment for up to ten years in total, depending on their risk of recurrence. For advanced breast cancer, it is usually continued for as long as it keeps the cancer under control. People with cirrhosis or severe liver impairment clear the drug more slowly and are usually prescribed the tablet every other day. Fertility use follows a different schedule. Letrozole is typically taken for five days early in the menstrual cycle, usually starting on day 2 or 3, beginning at 2.5 mg a day. If ovulation does not occur, the specialist may increase the dose in later cycles, up to 7.5 mg a day. Treatment starts only after pregnancy has been ruled out. Because the breast cancer and fertility regimens are so different, follow the instructions for your own prescription rather than another person's.
Many side effects of letrozole come from the low estrogen level it creates, and they resemble menopause symptoms. Hot flashes, sweating, joint pain and stiffness, muscle and bone aches, tiredness, headache, dizziness and swelling are among the most common during long-term breast cancer treatment. Joint pain in particular is worth raising early rather than simply putting up with it. Fatigue, dizziness or sleepiness can affect driving, so take care until you know how the medicine affects you. Over years of use, letrozole thins the bones. In a large study, about 15% of women taking letrozole had a fracture over roughly eight years, compared with about 11% on tamoxifen. Letrozole can also raise cholesterol. On the other hand, it caused fewer blood clots and far fewer cancers or overgrowth of the uterine lining than tamoxifen. The short courses used in fertility treatment do not carry the same long-term bone and cholesterol concerns as years of daily treatment.
Letrozole can harm a developing baby and must not be taken during pregnancy. Anyone on letrozole for breast cancer who could still become pregnant should use effective contraception during treatment and for at least three weeks after the last dose, and should contact the care team promptly if pregnancy is suspected. In fertility treatment, this is why a pregnancy test or other check comes before each course. Breastfeeding is not recommended during treatment or for at least three weeks afterward. Letrozole may also reduce fertility in both women and men who take it long term. Tamoxifen and letrozole are not taken together: tamoxifen lowers letrozole levels in the blood by about a third. When both are part of a plan, they are used one after the other. Tell the prescriber about liver disease, which can change the dose. Few other drug interactions are known, but the care team should still know about all prescriptions, over-the-counter medicines and supplements.
Letrozole for breast cancer is a long-term commitment. Its value lies in lowering the chance that the cancer comes back over many years, so it is continued even when there are no signs of cancer. Follow-up visits check for recurrence and side effects, and the care team may monitor bone density and cholesterol during treatment. If side effects make treatment difficult, discuss it before stopping, because adjustments or other hormone treatments may be possible. The decision about whether to continue beyond five years is individual. Longer treatment lowers the risk of recurrence and of a new cancer in the other breast, but it has not been shown to help people live longer, and bone effects increase with time. The size of the benefit depends on the original cancer, such as whether lymph nodes were involved, so the decision weighs that benefit against how well the medicine has been tolerated. In advanced breast cancer, letrozole is continued while scans and examinations show the cancer is controlled, and the plan changes if it starts to grow. In fertility treatment, the specialist checks whether each course has led to ovulation. Compared with clomiphene, letrozole leads to a live birth in about one additional woman out of every ten treated, with a similarly low chance of twins or other multiple pregnancy. If a course at the highest dose does not trigger ovulation, or no pregnancy follows after about six cycles with ovulation, the specialist usually moves to other options such as injectable fertility hormones.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Femara (Letrozole), what you've noticed, or ask the community a question.